top of page
Preclinical NASH/MASH and Metabolic Liver Disease Models
Non-alcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), is a progressive metabolic liver disease characterized by steatosis, inflammation, hepatocellular injury, and fibrosis.
IPS Therapeutique offers diet-induced mouse models of NASH/MASH to evaluate therapies targeting liver steatosis, inflammation, fibrosis, metabolic dysfunction, and progression toward advanced liver disease.
These models support assessment of liver histology, fibrosis, inflammatory markers, blood biochemistry, lipid metabolism, and treatment effects on metabolic liver injury.
bottom of page